Dyadic International DYAI
NASDAQ DYAI
$0.69 -0.01 (-1.43%)
At close: Aug 21, 2026 · 4:00 PM EDT

Dyadic International (DYAI) Income towards Parent Company (2018 - 2026)

Dyadic International (DYAI) posted Income towards Parent Company of -$1.9 million for Q1 2026, down 35.27% sequentially from -$1.4 million in Q4 2025, and up 3.66% YoY from -$1.9 million in Q1 2025.

Dyadic International (DYAI) Income towards Parent Company (2018 - 2026) Analysis & Trends

Dyadic International has reported Income towards Parent Company for 9 years, with the latest figure at -$1.9 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 3.66% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 26.5% YoY) and the FY2025 annual result came in at -$25.9 million, down 12.28% from the prior year.
  • Income towards Parent Company declined to -$1.9 million in Q1 2026 per DYAI's latest filing, from -$1.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$190216.0 in Q3 2024 and troughed at -$7.4 million in Q2 2022.
  • A 5-year average of -$2.5 million and a median of -$2.0 million in 2025 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 99.8% in 2022, then tumbled 924.01% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$2.3 million in 2022, then grew by 8.03% to -$2.1 million in 2023, then rose by 23.67% to -$1.6 million in 2024, then advanced by 8.97% to -$1.4 million in 2025, then sank by 35.27% to -$1.9 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.9 million, -$1.4 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Dyadic International 19.98 Mn 19.98 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.95 Mn
Dec 31, 2025 -1.44 Mn
Sep 30, 2025 -1.95 Mn
Jun 30, 2025 -1.89 Mn
Mar 31, 2025 -2.02 Mn
Dec 31, 2024 -1.58 Mn
Sep 30, 2024 -190,216.00
Jun 30, 2024 -1.92 Mn
Mar 31, 2024 -2.06 Mn
Dec 31, 2023 -2.07 Mn
Sep 30, 2023 -1.61 Mn
Jun 30, 2023 -2.18 Mn
Mar 31, 2023 -2.59 Mn
Dec 31, 2022 -2.25 Mn
Sep 30, 2022 -2.63 Mn
Jun 30, 2022 -7.43 Mn
Mar 31, 2022 -6.68 Mn
Dec 31, 2021 -12.63 Mn
Sep 30, 2021 -15.86 Mn
Jun 30, 2021 -9.83 Mn